Technological Advances in Glucose Management in Older Adults

Type 1 Diabetes Mellitus Clinical Trial

— TANGO  

Official title:

Technological Advances in Glucose Management in Older Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03078491
• Other study ID #: CHS #2016-29
• Status: Completed
• Phase: N/A
• Start date: March 30, 2017
• Est. completion date: October 1, 2022

Study information

• Verified date: February 2023
• Source: Joslin Diabetes Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study to assess the effectiveness of CGM (Continuous Glucose Monitor), enhanced by a diabetes management platform (DMP), collectively called enhanced CGM (eCGM), in the care of older patients with T1D. The DMP includes an automated data transfer from CGM, insulin-delivery devices, and activity tracker to a clinical decision support system (CDS) that provides dosing adjustment recommendations based on that data to the healthcare team. In addition, the DMP includes on-demand education for patients and caregivers, and an interface for communication between providers, patients, and their caregivers.

Description:

Hypoglycemia is a major and often devastating complication of T1D in the elderly. CGM has been shown to reduce the risk for hypoglycemia in adults with T1D including some more functional patients over 65 years old. However, the Medicare population is heterogeneous and may have age-related clinical and functional impairments that can impact self-care. These patients will require additional targeted guidance and support to fully realize the potential benefits of CGM. To address these age-specific barriers which could limit the effective use of CGM, in our planned RCT (Specific Aim 1) the use of CGM will be coupled with the DMP (Diabetes Management Platform), a tablet-based technology platform ( termed enhanced CGM (eCGM)). The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The use of the DMP is expected to help the less technologically proficient Medicare patients to derive benefit from CGM. Specific Aim 2 will involve extensive mixed methods research (including semi-structured interviews of patients and caregivers) directed at making an in-depth assessment of barriers to the use of diabetes technology in older adults. This investigation will provide the evidence-base for future improvements in both the technology and clinical approach to the training of older adults and their caregivers. Specific Aim 3 will involve a cost-effectiveness analysis of the technology system (CGM with DMP = enhanced CGM [eCGM]) used in the trial as well as quality of life measures, providing a foundation for decision-making on coverage.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 168
• Est. completion date: October 1, 2022
• Est. primary completion date: September 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Patients with age = 65 years

• Community-living

• Clinical diagnosis of T1D

• On multiple insulin injections (=3 injection/s day) or insulin pump.

Exclusion Criteria:

• Use of real-time CGM in past 2 years

• A1c > 10% (since individuals with very poor glycemic control usually have barriers to optimal self-care that preclude effective use of technology)

• Use of insulin pump that cannot be uploaded for CDS

• Unable or unwilling to perform task needed for study participation during the run-in period

• Severe vision or hearing impairment that could interfere with study tasks

• Need to use acetaminophen on regular basis (since can interfere with CGM accuracy)

• Living in an institutional setting (e.g. group homes, nursing homes)

• Terminal diseases with life expectancy < 1 year (e.g. malignancy)

• Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living)

• Alcohol or other drug abuse

• Conditions that impact wear of CGM (e.g. CHF with edema, skin conditions); and

• End stage renal insufficiency (eGFR<30), or on dialysis (since impact of fluid shift on sensor lag not clearly understood).

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Hypoglycemia
• Older Adults
• Type 1 Diabetes Mellitus

Intervention

Other:
• eCGM (enhanced CGM)
Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.

Locations

Country	Name	City	State
United States	Joslin Diabetes Center	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Joslin Diabetes Center	Beth Israel Deaconess Medical Center, Boston Children's Hospital, RTI International

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in duration of hypoglycemia	Minutes per day CGM < 70 mg/dL assessed over 2 weeks CGM use (blinded in the control arm; unblinded in the treatment arm)	change of duration of hypoglycemia(minutes/day) from baseline to 6 months between intervention and control groups
Secondary	Fasting and bedtime CGM glucose values per day	Difference from fasting and bedtime CGM glucose values per day	change in glucose values(mg/dl) from baseline to 6 months between intervention and control groups
Secondary	Severe biochemical hypoglycemia	Incidence of severe biochemical hypoglycemia (defined as CGM below 54mg/dL for > than 20 minutes) assessed over 2 weeks CGM use (blinded in the control arm; unblinded in the treatment arm)	change in severe biochemical hypoglycemia (episodes per day) from baseline to 6 months between intervention and control groups
Secondary	Severe clinical hypoglycemia	Incidence of clinically severe hypoglycemia (requiring third party assistance or loss of consciousness) measured by clinical history,	change in severe clinical hypoglycemia (episodes per day) from baseline to 6 months between intervention and control groups
Secondary	Hemoglobin A1C	A1C measured by laboratory test	Change in A1C (%) from baseline to 6 months between intervention and control groups
Secondary	Cost-effectiveness and cost-utility	cost-effectiveness and cost-utility of using eCGM versus usual care with self-monitoring glucose monitoring by calculating the incremental cost-effectiveness ratios	6 months
Secondary	Barriers and facilitators of CGM use	Mixed-method approach using semi-structured interviews to assess barriers and facilitators in those participants who fail the pretrial run-in and those who derive benefits from eCGM	6 months